249 related articles for article (PubMed ID: 29144116)
1. [The importance of biosimilars medicines for private and statutory health insurance].
Bretthauer B
Versicherungsmedizin; 2016 Dec; 68(4):173-5. PubMed ID: 29144116
[TBL] [Abstract][Full Text] [Related]
2. [Biosimilars and the efficiency principle].
Münnch T
Laryngorhinootologie; 2017 Dec; 96(12):828-830. PubMed ID: 29195262
[TBL] [Abstract][Full Text] [Related]
3. [Can we transfer the mechanisms of the generics market to biosimilars?].
Jacke CO; Wild F
Versicherungsmedizin; 2016 Dec; 68(4):168-72. PubMed ID: 29144113
[TBL] [Abstract][Full Text] [Related]
4. [Biosimilars - Potential, risks and open questions].
Dtsch Med Wochenschr; 2014 Jan; 139(1-2):12-3. PubMed ID: 24551883
[No Abstract] [Full Text] [Related]
5. [The physician caught between two chairs. Comments on the difficulty in dealing with off-label use].
Harder Yv
Urologe A; 2007 Oct; 46(10):1429-34. PubMed ID: 17786403
[No Abstract] [Full Text] [Related]
6. [The rheumatologist's conflict between "off-label" prescription and failure to render assistance].
Hellmich B; Gross WL
Z Rheumatol; 2003 Feb; 62(1):34-5. PubMed ID: 12624800
[No Abstract] [Full Text] [Related]
7. Economic evaluation for pharmaceuticals in Germany.
Jönsson B
Eur J Health Econ; 2007 Sep; 8 Suppl 1():S1-2. PubMed ID: 17638033
[No Abstract] [Full Text] [Related]
8. Obstacles to the Adoption of Biosimilars for Chronic Diseases.
Hakim A; Ross JS
JAMA; 2017 Jun; 317(21):2163-2164. PubMed ID: 28459924
[No Abstract] [Full Text] [Related]
9. [Family physicians resist high prescription risk].
Schmidt K
MMW Fortschr Med; 2003 May; 145(20):58. PubMed ID: 12822233
[No Abstract] [Full Text] [Related]
10. [Co-payment and the hospital pharmacy].
Lamas Díaz MJ; Delgado Sánchez O; Poveda Andrés JL
Farm Hosp; 2013; 37(5):345-7. PubMed ID: 24128094
[No Abstract] [Full Text] [Related]
11. Drug coverage insurance as a novel element of private health insurance in Poland.
Czerw A; Religioni U
Acta Pol Pharm; 2013; 70(4):763-7. PubMed ID: 23923401
[TBL] [Abstract][Full Text] [Related]
12. Coverage for Biosimilars vs Reference Products Among US Commercial Health Plans.
Chambers JD; Lai RC; Margaretos NM; Panzer AD; Cohen JT; Neumann PJ
JAMA; 2020 May; 323(19):1972-1973. PubMed ID: 32427297
[TBL] [Abstract][Full Text] [Related]
13. Decision making in Germany: is health economic evaluation as a supporting tool a sleeping beauty?
Gerber-Grote A; Sandmann FG; Zhou M; Ten Thoren C; Schwalm A; Weigel C; Balg C; Mensch A; Mostardt S; Seidl A; Lhachimi SK
Z Evid Fortbild Qual Gesundhwes; 2014; 108(7):390-6. PubMed ID: 25444297
[TBL] [Abstract][Full Text] [Related]
14. [Impact of demographic chance on pharmaceutical expenses in private health insurance--a scenario-based analysis].
Böcking W; Tidelski O; Skuras B; Bäumler A; Kitzmann F
Dtsch Med Wochenschr; 2012 Aug; 137(31-32):1595-600. PubMed ID: 22872541
[TBL] [Abstract][Full Text] [Related]
15. Lower Prices and Greater Patient Access - Lessons from Germany's Drug-Purchasing Structure.
Robinson JC
N Engl J Med; 2020 Jun; 382(23):2177-2179. PubMed ID: 32492300
[No Abstract] [Full Text] [Related]
16. Pharmaceuticals and Medical Devices: Cost Savings.
Steiner DJ;
Issue Brief Health Policy Track Serv; 2016 Dec; 2016():1-31. PubMed ID: 28252884
[No Abstract] [Full Text] [Related]
17. [Off-label therapy from the perspective of the medical insurance service].
Grell L; Rieger M
Z Rheumatol; 2012 Feb; 71(2):101-4, 106-7. PubMed ID: 22370800
[TBL] [Abstract][Full Text] [Related]
18. Can a health care system change?
Lexchin J
CMAJ; 1997 Sep; 157(5):507-8. PubMed ID: 9294383
[No Abstract] [Full Text] [Related]
19. [Does red-green destroy phytotherapy?].
Krankenpfl J; 2003; 41(4-6):111. PubMed ID: 12929322
[No Abstract] [Full Text] [Related]
20. [An end to scurrilous recommendations on the new regulation. What is still allowed on the insurance form?].
Schmidt K
MMW Fortschr Med; 2004 Apr; 146(15):60-2. PubMed ID: 15373023
[No Abstract] [Full Text] [Related]
[Next] [New Search]
